Tulasigeri M. Totiger

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Skye Montoya, Jessie Bourcier, Mark Noviski et al. · Science · 2024 · 148 citations · Full text

Medicine, Molecular Biology, Oncology +15

Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer

Tulasigeri M. Totiger, Supriya Srinivasan, Venkatakrishna R. Jala et al. · Molecular Cancer Therapeutics · 2018 · 118 citations · Full text

Medicine, Oncology, Pharmacology +17

Prostate Cancer Targeted X-Ray Fluorescence Imaging via Gold Nanoparticles Functionalized With Prostate-Specific Membrane Antigen (PSMA)

Daiki Hara, Wensi Tao, Tulasigeri M. Totiger et al. · International Journal of Radiation Oncology*Biology*Physics · 2021 · 50 citations · Full text

Pharmacy, Oncology, Pharmaceutics +17

E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial

Jan Philipp Bewersdorf, Maximilian Stahl, Justin Taylor et al. · Leukemia · 2023 · 50 citations · Full text

Medicine, Oncology, Pharmacology +8

Tobacco Carcinogen–Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer

Supriya Srinivasan, Tulasigeri M. Totiger, Chanjuan Shi et al. · Cancer Research · 2018 · 44 citations · Full text

Medicine, Cancer Biology, Molecular Biology +16